Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort
- Gatto M.
- Saccon F.
- Andreoli L.
- Bartoloni E.
- Benvenuti F.
- Bortoluzzi A.
- Bozzolo E.
- Brunetta E.
- Canti V.
- Cardinaletti P.
- Ceccarelli F.
- Ciccia F.
- Conti F.
- De Marchi G.
- de Paulis A.
- De Vita S.
- Emmi G.
- Faggioli P.
- Fasano S.
- Fredi M.
- Gabrielli A.
- Gasparotto M.
- Gerli R.
- Gerosa M.
- Govoni M.
- Gremese E.
- Laria A.
- Larosa M.
- Mosca M.
- Orsolini G.
- Pazzola G.
- Petricca L.
- Ramirez G. A.
- Regola F.
- Rossi F. W.
- Rossini M.
- Salvarani C.
- Scarpato S.
- Tani C.
- Tincani A.
- Ubiali T.
- Urban M. L.
- Zen M.
- Doria A.
- Iaccarino L.
DOIAbstract
Background: Belimumab was recently approved for treatment of lupus glomerulonephritis (LN). Aim: To evaluate renal response and its predictors in LN patients receiving belimumab in real-life. Patients and methods: We considered all patients fulfilling the SLEDAI-2K renal items and/or having estimated glomerular filtration rate (eGFR)≤60 ml/min/1.73 m2, with positive anti-dsDNA and/or low C3/C4 enrolled in the multicentre Italian lupus cohort BeRLiSS (BElimumab in Real LIfe Setting Study), treated with monthly IV Belimumab 10 mg/kg over standard treatment. Primary efficacy renal response (PERR), defined as proteinuria ≤0.7 g/24 h, eGFR≥60 ml/min/1.73 m2 without rescue therapy, was considered as primary outcome. Complete renal response (CRR; ...
Add to ORKG